PROPERTIES OF MOUSE LEUKEMIA VIRUSES .17. FACTORS REQUIRED FOR SUCCESSFUL TREATMENT OF SPONTANEOUS AKR LEUKEMIA BY ANTIBODIES AGAINST GP71
PROPERTIES OF MOUSE LEUKEMIA VIRUSES .17. FACTORS REQUIRED FOR SUCCESSFUL TREATMENT OF SPONTANEOUS AKR LEUKEMIA BY ANTIBODIES AGAINST GP71
复制标题
DOI：
10.1016/0042-6822(81)90358-5
复制
发表时间：
1981-01-01
期刊：
影响因子：
3.7
通讯作者：
SCHAFER, W
中科院分区：
文献类型：
--
作者：
SCHWARZ, H;IHLE, JN;SCHAFER, W
AKR mice were treated with heterologous anti-gp71 antibodies under various conditions to establish the optimal criteria for effective suppression of leukemia development. The strongest effect was observed when mice were treated at birth; when this regimen was used, prior treatment of the mothers did not provide additional protection. If treatment was delayed until day 3, the beneficial effect of the serum diminished sharply, emphasizing the presence of a narrow window very early in the life of the AKR mouse when antibody must be present to have an effect on subsequent leukemia development. A number of parameters were examined in the experimental mice and as in a previous study, suppression of leukemia, which occurred in 68% of the animals, correlated with elimination of viremia and appearance of natural antiviral antibodies. The results suggest that antibody therapy is primarily effective against the thymic form of the disease. The availability of nonviremic, antibody-positive animals afforded the opportunity to examine if these characteristics could be transmitted to the offspring. From selected mating crosses, F1 and F2 generations of AKR mice were successfully derived which possessed high titers of antiviral antibodies and were nonviremic at 21-28 wk of age. A maternal effect may be responsible for this phenomenon. The implications of these findings are discussed in relation to AKR leukemogenesis.
